Eli Lilly & Co. may be known for its leadership in the diabetes space, but the Indianapolis pharma is quietly building up its presence in oncology hoping one day this franchise will be just as prominent. During an investor event with stakeholders on May 24, Lilly laid out its oncology strategy.
"So, I think we're at a really seminal moment [in oncology], however, with all the progress there's still issues," Lilly...